Sumanta K. Pal, MD, FASCO, on Tolerability of Lenvatinib and Everolimus to Treat Patients With RCC

Pal detailed the phase 2 trial of lenvatinib at 2 starting doses plus everolimus to treat patients with renal cell carcinoma.

Sumanta K. Pal, MD, FASCO, spoke with CancerNetwork® to detail a phase 2 trial (NCT03173560) of lenvatinib (Lenvima) at 2 starting doses and everolimus to treat patients with renal cell carcinoma, discussing challenges with tolerability of the drugs from a presentation at the 2021 Genitourinary Cancers Symposium.

Transcription:

This particular combination with lenvatinib and everolimus doesn’t include an [immunotherapy] component, it’s just pure targeted therapy. And I would suggest that, in terms of tolerability, it has its challenges. I was hoping that perhaps we could get away with using a lower dose and thereby mitigate some toxicity, but it doesn’t appear that that’s the case. It certainly does suggest to me that perhaps there are challenges as we try to implement the higher dose of lenvatinib with pembrolizumab. [In the CLEAR study (NCT02811861)], they use a dose of 20 mg of lenvatinib, but I can't imagine that that's going to be any easier for patients.

Reference:

Pal SK, Puente J, Heng DYK, et al. Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): Results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI). Presented at: 2021 Genitourinary Cancers Symposium. Abstract 307.

Related Videos
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.
A recovery tracker and other digital tools may be useful in helping to manage patient symptoms following debulking surgery for gynecologic cancer, according to an expert from Memorial Sloan Kettering Cancer Center.
According to an expert from University Hospitals, integrative oncology has a place in the treatment of patients with kidney cancer alongside palliative care, psycho-oncology, and physical therapy.
Common symptoms following debulking surgery for gynecologic cancer appear to include pain, diarrhea, and nausea, according to an expert from Memorial Sloan Kettering Cancer Center.
According to an expert from University Hospitals, oncologists should work together and look for opportunities to improve patients’ diets and exercise routines to mitigate symptoms of kidney cancer and associated treatment.
According to an expert from University Hospitals, studying pathways related to inflammation, epigenetics, and the microbiome may elucidate how patients with kidney cancer respond to anti-cancer therapy.
Patients who use a recovery tracker tool appear to experience lower hospital readmission rates following gynecologic cancer debulking surgery compared with those who did not.